Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Lexeo Therapeutics announced the publication of Phase I/II data for its gene therapy LX2006 in JAMA Cardiology, showing the treatment was generally well-tolerated with early signs of efficacy in Friedreich ataxia. Data from 17 participants demonstrated mean improvements in Left Ventricular Mass Index (LVMI) of 28% at 6 months and 33% at 12 months in mid- and high-dose cohorts, alongside improvements in cardiac biomarkers and frataxin expression.
Key figures
- Phase Of Trial
- Phase I/II
- Participants phase 1 2
- 17
- Participants sunrise fa
- 8
- Lvmi improvement 6 months
- 28%
- Lvmi improvement 12 months
- 33%
- Participants weill cornell
- 9
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.